# Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

> **NCT06678074** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Implicit Bioscience** · enrollment: 10 (estimated)

## Conditions studied

- STEMI
- STEMI (ST Elevation MI)
- STEMI - ST Elevation Myocardial Infarction (MI)
- Stent Implantation

## Interventions

- **DRUG:** Atibuclimab (IC14), 20 mg/kg intravenously, once
- **OTHER:** Placebo, 150 mL intravenously, once

## Key facts

- **NCT ID:** NCT06678074
- **Lead sponsor:** Implicit Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-06
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06678074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06678074, "Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06678074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*